A Phase 3, Randomized, Open-label, Study to Compare the Efficacy and Safety of Adjuvant MK-2870 in Combination with Pembrolizumab (MK-3475) Versus Treatment of Physician’s Choice (TPC) in Participants With Triple-Negative Breast Cancer (TNBC) Who Received Neoadjuvant Therapy and Did Not Achieve a Pathological Complete Response (pCR) at Surgery.

PI Dr. Claudio Vernieri   

A Phase 3, randomized, 1:1, open-label study using the investigational drug MK-2870 in patients with triple-negative breast cancer (TNBC). The study design includes two arms (ARM A: MK-2870 + Pembrolizumab, ARM B: standard therapy of investigator's choice). Inclusion criteria are failure to respond completely to at least five cycles of chemotherapy and pembrolizumab (including one cycle of neoadjuvant anthracyclines) and centralized confirmation of triple-negative breast cancer.